Meibomianitis (Meibomitis): Causes and Treatments -CEW

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== Meibomianitis (Meibomitis): Causes and Treatments ======
FIXME

Meibomianitis refers to inflammation of the meibomian glands, a subtype of posterior blepharitis. It is classified as a form of meibomian gland dysfunction (MGD) and is the most common cause of evaporative dry eye disease[[https://pubmed.ncbi.nlm.nih.gov/29652164|Clayton JA, NEJM 2018]].

===== Definition =====

The International Workshop on Meibomian Gland Dysfunction defines MGD as a "chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion"[[https://pubmed.ncbi.nlm.nih.gov/34125203|Onghanseng et al., Cochrane 2021]]. When MGD is accompanied by clinically apparent inflammation — visible lid margin redness, telangiectasia, and turbid or thickened secretions — it is termed **meibomitis** or **meibomianitis**[[https://pubmed.ncbi.nlm.nih.gov/30481812|Suzuki T, IOVS 2018]].

===== Causes and Risk Factors =====

=== Obstructive Mechanisms ===

  * **Hyperkeratinization** of the meibomian gland duct epithelium leads to terminal duct obstruction, reduced meibum secretion, cystic dilation, and eventual acinar atrophy[[https://doi.org/10.1002/14651858.CD013029.pub2|Cote et al., Cochrane 2020]].*
  * Stagnation of meibum within obstructed glands promotes bacterial proliferation and secondary inflammation[[https://pubmed.ncbi.nlm.nih.gov/30481812|Suzuki T, IOVS 2018]].

=== Microbial Factors ===

  * **Bacterial colonization** — Proliferation of commensal bacteria (e.g., //Staphylococcus// spp.) within the meibomian glands produces lipolytic enzymes that alter meibum composition and drive inflammation[[https://pubmed.ncbi.nlm.nih.gov/36930236|Upaphong et al., JAMA Ophthalmology 2023]].
  * **//Demodex// mite infestation** — //Demodex brevis// inhabits the meibomian glands and can block gland orifices, inducing MGD and secondary meibomitis. //Demodex folliculorum// infests the eyelash follicles and may cause anterior blepharitis that coexists with posterior disease. Cylindrical dandruff at the lash base is highly suggestive of Demodex infestation[[https://pubmed.ncbi.nlm.nih.gov/34125203|Onghanseng et al., Cochrane 2021]][[https://pubmed.ncbi.nlm.nih.gov/30885709|Rabensteiner et al., AJO 2019]].

=== Systemic and Dermatologic Associations ===

  * **Acne rosacea** — One of the most important systemic associations; ocular rosacea frequently manifests as posterior blepharitis/meibomitis[[https://pubmed.ncbi.nlm.nih.gov/29652164|Clayton JA, NEJM 2018]].
  * **Seborrheic dermatitis** — Oily, greasy scaling of the lid margin with overlap into MGD[[https://pubmed.ncbi.nlm.nih.gov/34125203|Onghanseng et al., Cochrane 2021]].
  * **Fibrosing conjunctival disorders** — Trachoma, erythema multiforme, and ocular cicatricial pemphigoid can cause secondary MGD[[https://pubmed.ncbi.nlm.nih.gov/29652164|Clayton JA, NEJM 2018]].

=== Hormonal and Age-Related Factors ===

  * Androgen deficiency reduces meibocyte lipid production via downregulation of androgen receptor (AR) and PPARγ signaling, contributing to altered meibum composition and gland atrophy[[https://pubmed.ncbi.nlm.nih.gov/41831668|Yang & Li, Exp Eye Res 2026]].
  * Prevalence of MGD increases significantly with age, particularly above 50 years[[https://doi.org/10.1002/14651858.CD016127|Kam et al., Cochrane 2026]].

=== Other Contributing Factors ===

  * Use of **isotretinoin** (causes meibomian gland atrophy)[[https://pubmed.ncbi.nlm.nih.gov/34125203|Onghanseng et al., Cochrane 2021]].*
  * Contact lens wear, giant papillary conjunctivitis, and environmental factors (low humidity, prolonged screen use).

===== Treatments =====

=== Conservative / First-Line Therapy ===

  * **Warm compresses** — Soften meibum, relieve duct obstruction, and improve gland function. Recommended as the mainstay of treatment[[https://pubmed.ncbi.nlm.nih.gov/29652164|Clayton JA, NEJM 2018]].
  * **Lid hygiene** — Mechanical cleansing of the eyelid margins (eyelid scrubs, baby shampoo, or commercial lid wipes) reduces bacterial load[[https://pubmed.ncbi.nlm.nih.gov/29652164|Clayton JA, NEJM 2018]][[https://pubmed.ncbi.nlm.nih.gov/26130187|Thode & Latkany, Drugs 2015]].
  * **Meibomian gland expression/massage** — Manual expression of inspissated meibum from the glands[[https://pubmed.ncbi.nlm.nih.gov/26130187|Thode & Latkany, Drugs 2015]].
  * **Artificial tears** — Lipid-containing lubricants to supplement the deficient tear film lipid layer.

=== Topical Pharmacological Therapy ===

  * **Topical antibiotics** — Azithromycin ophthalmic solution has both antibacterial and anti-inflammatory properties[[https://pubmed.ncbi.nlm.nih.gov/29652164|Clayton JA, NEJM 2018]].
  * **Topical corticosteroids** — Short courses of low-dose glucocorticoids (e.g., loteprednol etabonate) for acute flares; requires monitoring for steroid-induced glaucoma and cataracts[[https://pubmed.ncbi.nlm.nih.gov/29652164|Clayton JA, NEJM 2018]][[https://pubmed.ncbi.nlm.nih.gov/26130187|Thode & Latkany, Drugs 2015]].
  * **Antibiotic–steroid combinations** — Topical combination drops/ointments for moderate-to-severe disease[[https://pubmed.ncbi.nlm.nih.gov/38350160|Rocha et al., JCRS 2024]].
  * **Topical cyclosporine A** (Restasis, Cequa) — Immunomodulatory agent approved for dry eye disease; may be used as an adjunct, though evidence for superiority over placebo in MGD specifically is limited[[https://doi.org/10.1002/14651858.CD010051.pub2|de Paiva et al., Cochrane 2019]].
  * **Lifitegrast 5%** (Xiidra) — LFA-1/ICAM-1 antagonist approved for dry eye; has shown benefit in inflammatory MGD, with improvement in eye dryness, corneal staining, and eyelid redness compared with thermal pulsation in one RCT[[https://pubmed.ncbi.nlm.nih.gov/31895884|Tauber J, Cornea 2020]].

=== Systemic Pharmacological Therapy ===

  * **Oral tetracyclines** — Doxycycline (e.g., 50–100 mg daily for 6–12 weeks) or minocycline; exert anti-inflammatory, lipid-modulating, and anti-bacterial effects on the meibomian glands[[https://pubmed.ncbi.nlm.nih.gov/29652164|Clayton JA, NEJM 2018]][[https://pubmed.ncbi.nlm.nih.gov/36930236|Upaphong et al., JAMA Ophthalmology 2023]].
  * **Oral azithromycin** — Pulsed regimens (e.g., 500 mg day 1, then 250 mg days 2–5) offer a shorter course with fewer gastrointestinal side effects; one RCT showed comparable or superior efficacy to doxycycline[[https://pubmed.ncbi.nlm.nih.gov/36930236|Upaphong et al., JAMA Ophthalmology 2023]].
  * **Omega-3 fatty acid supplementation** — May improve MGD symptoms and tear film stability[[https://pubmed.ncbi.nlm.nih.gov/26130187|Thode & Latkany, Drugs 2015]].

=== Demodex-Directed Therapy ===

  * **Tea tree oil** (terpinen-4-ol) — Effective for MGD associated with //Demodex// infestation; applied as lid scrubs[[https://pubmed.ncbi.nlm.nih.gov/26130187|Thode & Latkany, Drugs 2015]].
  * **Lotilaner 0.25% ophthalmic solution** (Xdemvy) — FDA-approved for Demodex blepharitis.

=== In-Office Procedural Treatments ===

  * **Thermal pulsation (LipiFlow)** — Automated device applying controlled heat (41–43°C) and pulsatile pressure to the eyelids for 12 minutes; may improve meibomian gland function and dry eye symptoms compared with warm compresses, though long-term durability is uncertain[[https://pubmed.ncbi.nlm.nih.gov/38085025|Tao et al., AAO 2023]].
  * **Intense pulsed light (IPL) therapy** — Broad-spectrum light applied to the periocular skin; when combined with meibomian gland expression, may improve tear film stability, ocular surface staining, and lipid layer thickness[[https://pubmed.ncbi.nlm.nih.gov/38227935|McCann et al., JAMA Ophthalmology 2024]].
  * **Meibomian gland probing** — Intraductal probing to relieve obstruction in refractory cases[[https://pubmed.ncbi.nlm.nih.gov/31494111|Sabeti et al., Surv Ophthalmol 2019]].
  * **Other thermal devices** — TearCare, MiBoFlo, and Systane iLux systems offer alternative in-office heat/expression modalities[[https://pubmed.ncbi.nlm.nih.gov/38085025|Tao et al., AAO 2023]].

===== Complications of Untreated Meibomianitis =====

If left untreated, meibomitis can cause inflammation of the adjacent ocular surface, leading to:

  * **Meibomian keratoconjunctivitis** — corneal cellular infiltrates, neovascularization, and superficial punctate keratopathy[[https://pubmed.ncbi.nlm.nih.gov/30481812|Suzuki T, IOVS 2018]].
  * Progressive **meibomian gland dropout** (acinar atrophy), which is considered a permanent pathological change[[https://doi.org/10.1002/14651858.CD013029.pub2|Cote et al., Cochrane 2020]].
  * Chronic evaporative **dry eye disease**[[https://pubmed.ncbi.nlm.nih.gov/29652164|Clayton JA, NEJM 2018]].

=====References=====

1. Oral Antibiotics for Chronic Blepharitis. Onghanseng N, Ng SM, Halim MS, Nguyen QD. The Cochrane Database of Systematic Reviews. 2021;6:CD013697. doi:10.1002/14651858.CD013697.pub2.
2. Dry Eye. Clayton JA. The New England Journal of Medicine. 2018;378(23):2212-2223. doi:10.1056/NEJMra1407936.
3. Inflamed Obstructive Meibomian Gland Dysfunction Causes Ocular Surface Inflammation. Suzuki T. Investigative Ophthalmology & Visual Science. 2018;59(14):DES94-DES101. doi:10.1167/iovs.17-23345.
4. Molecular Mechanisms and Pathophysiology of Meibomian Gland Dysfunction. Yang L, Li Z. Experimental Eye Research. 2026;267:110970. doi:10.1016/j.exer.2026.110970.
5. A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction. Tauber J. Cornea. 2020;39(4):403-407. doi:10.1097/ICO.0000000000002235.
6. Pharmacological, Natural and Emerging Therapies for Meibomian Gland Dysfunction: A Review. Cooper JM, Mahmoud R, Jennings CJ, et al. Drugs. 2026;86(5):675-718. doi:10.1007/s40265-025-02241-6.
7. Pulsed Oral Azithromycin vs 6-Week Oral Doxycycline for Moderate to Severe Meibomian Gland Dysfunction: A Randomized Clinical Trial. Upaphong P, Tangmonkongvoragul C, Phinyo P. JAMA Ophthalmology. 2023;141(5):423-429. doi:10.1001/jamaophthalmol.2023.0302.
8. Oral Antibiotics for Meibomian Gland-Related Ocular Surface Disease: A Report by the American Academy of Ophthalmology. Wladis EJ, Bradley EA, Bilyk JR, Yen MT, Mawn LA. Ophthalmology. 2016;123(3):492-6. doi:10.1016/j.ophtha.2015.10.062.
9. Interventions for Dry Eye: An Overview of Systematic Reviews. McCann P, Kruoch Z, Lopez S, et al. JAMA Ophthalmology. 2024;142(1):58-74. doi:10.1001/jamaophthalmol.2023.5751.
10. Thermal Pulsation in the Management of Meibomian Gland Dysfunction and Dry Eye: A Report by the American Academy of Ophthalmology. Tao JP, Shen JF, Aakalu VK, et al. Ophthalmology. 2023;130(12):1336-1341. doi:10.1016/j.ophtha.2023.07.009.
11. Intense Pulsed Light (IPL) Therapy for the Treatment of Meibomian Gland Dysfunction. Cote S, Zhang AC, Ahmadzai V, et al. The Cochrane Database of Systematic Reviews. 2020;3:CD013559. doi:10.1002/14651858.CD013559.